Neuro-oncology perspective of treatment options in metastatic breast cancer.
暂无分享,去创建一个
[1] V. Prasad,et al. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study , 2018, British Medical Journal.
[2] Edward S. Kim,et al. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Soffietti,et al. Imaging and clinical end points in brain metastases trials. , 2017, CNS oncology.
[4] W. Curran,et al. Single-Fraction Stereotactic Radiosurgery (SRS) Alone Versus Surgical Resection and SRS for Large Brain Metastases: A Multi-institutional Analysis. , 2017, International journal of radiation oncology, biology, physics.
[5] A. Akabane,et al. A Multi-institutional Prospective Observational Study of Stereotactic Radiosurgery for Patients With Multiple Brain Metastases (JLGK0901 Study Update): Irradiation-related Complications and Long-term Maintenance of Mini-Mental State Examination Scores. , 2017, International journal of radiation oncology, biology, physics.
[6] J. Buckner,et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. , 2017, The Lancet. Oncology.
[7] P. Wen,et al. Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study , 2017, JAMA oncology.
[8] Nicholas B. Levine,et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. , 2017, The Lancet. Oncology.
[9] N. Turner,et al. Targeting PIK3CA-mutant advanced breast cancer in the clinical setting. , 2017, The Lancet. Oncology.
[10] M. Robson,et al. OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). , 2017 .
[11] E. Perez,et al. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial , 2017, Breast Cancer Research and Treatment.
[12] E. Winer,et al. TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM). , 2017 .
[13] A. Seidman,et al. Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis , 2017, Clinical breast cancer.
[14] S. Chia,et al. Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC) , 2017, Clinical Cancer Research.
[15] Sung-Bae Kim,et al. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial. , 2016, JAMA oncology.
[16] C. Anders,et al. Multidisciplinary Management of Breast Cancer Brain Metastases. , 2016, Oncology.
[17] E. Winer,et al. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] H. Lanfermann,et al. Radiation injury versus malignancy after stereotactic radiosurgery for brain metastases: impact of time-dependent changes in lesion morphology on MRI , 2016, Neuro-oncology.
[19] H. Steiger,et al. 5-ALA fluorescence of cerebral metastases and its impact for the local-in-brain progression , 2016, Oncotarget.
[20] W. Curran,et al. Comparing Preoperative With Postoperative Stereotactic Radiosurgery for Resectable Brain Metastases: A Multi-institutional Analysis. , 2016, Neurosurgery.
[21] Volker W Stieber,et al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. , 2016, JAMA.
[22] V. Esposito,et al. Single-Fraction Versus Multifraction (3 × 9 Gy) Stereotactic Radiosurgery for Large (>2 cm) Brain Metastases: A Comparative Analysis of Local Control and Risk of Radiation-Induced Brain Necrosis. , 2016, International journal of radiation oncology, biology, physics.
[23] Kwang Hee Kim,et al. Eribulin Mesylate Combined with Local Treatment for Brain Metastasis from Breast Cancer: Two Case Reports , 2016, Journal of breast cancer.
[24] L. Carey,et al. Changing Natural History of HER2–Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies , 2016, Clinical breast cancer.
[25] S. Tolaney,et al. Assessment of concentrations of abemaciclib and its major active metabolites in plasma, CSF, and brain tumor tissue in patients with brain metastases secondary to hormone receptor positive (HR+) breast cancer. , 2016 .
[26] G. Romieu,et al. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases , 2016, Breast Cancer Research and Treatment.
[27] A. Viale,et al. Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] D. Vordermark,et al. Radiotherapy of brain metastases from breast cancer: Treatment results and prognostic factors. , 2016, Oncology letters.
[29] Ricardo J. Komotar,et al. The role of 5-aminolevulinic acid in brain tumor surgery: a systematic review , 2016, Neurosurgical Review.
[30] Chien-Kuo Wang,et al. Differentiating Radiation-Induced Necrosis from Recurrent Brain Tumor Using MR Perfusion and Spectroscopy: A Meta-Analysis , 2016, PloS one.
[31] Robert T. Jones,et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.
[32] H. Steiger,et al. Early postoperative magnet resonance tomography after resection of cerebral metastases , 2015, Acta Neurochirurgica.
[33] Martin Bendszus,et al. Response assessment criteria for brain metastases: proposal from the RANO group. , 2015, The Lancet. Oncology.
[34] E. Shaw,et al. Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] J. Olson,et al. Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases , 2015, Journal of Neuro-Oncology.
[36] Akash J. Patel,et al. Impact of surgical methodology on the complication rate and functional outcome of patients with a single brain metastasis. , 2015, Journal of neurosurgery.
[37] Yasuyoshi Watanabe,et al. 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients , 2015, EJNMMI Research.
[38] Chiun-Sheng Huang,et al. Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy , 2015, Clinical Cancer Research.
[39] R. Weil,et al. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. , 2015, Neuro-oncology.
[40] S. Margolin,et al. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Lang Li,et al. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients , 2015, Journal of Neuro-Oncology.
[42] K. Blackwell,et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[43] Wolfgang A Tome,et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] J. Suh. Hippocampal-avoidance whole-brain radiation therapy: a new standard for patients with brain metastases? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] P. Wen,et al. Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. , 2014, Neuro-oncology.
[46] J. Baselga,et al. Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. , 2014, The oncologist.
[47] Satoshi Suzuki,et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. , 2014, The Lancet. Oncology.
[48] Walter F. Wiggins,et al. A new treatment paradigm: neoadjuvant radiosurgery before surgical resection of brain metastases with analysis of local tumor recurrence. , 2014, International journal of radiation oncology, biology, physics.
[49] B. Lippitz,et al. Stereotactic radiosurgery in the treatment of brain metastases: the current evidence. , 2014, Cancer treatment reviews.
[50] Samuel T Chao,et al. Challenges with the diagnosis and treatment of cerebral radiation necrosis. , 2013, International journal of radiation oncology, biology, physics.
[51] M. Mehta,et al. Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the graded prognostic assessment (GPA). , 2013, International journal of radiation oncology, biology, physics.
[52] P. Brown,et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. , 2013, Neuro-oncology.
[53] C. Perou,et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[54] M. Duffy,et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer , 2013, Oncotarget.
[55] V. Esposito,et al. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. , 2013, International journal of radiation oncology, biology, physics.
[56] M. Dimopoulos,et al. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis , 2013, Breast Cancer Research and Treatment.
[57] Li Ding,et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.
[58] P. Venuturumilli,et al. Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases , 2013, Acta oncologica.
[59] Steven D Chang,et al. Risk of leptomeningeal disease in patients treated with stereotactic radiosurgery targeting the postoperative resection cavity for brain metastases. , 2012, International journal of radiation oncology, biology, physics.
[60] S. Ambudkar,et al. Neratinib Reverses ATP-Binding Cassette B1-Mediated Chemotherapeutic Drug Resistance In Vitro, In Vivo, and Ex Vivo , 2012, Molecular Pharmacology.
[61] J. Joo,et al. Risk for leptomeningeal seeding after resection for brain metastases: implication of tumor location with mode of resection. , 2012, Journal of neurosurgery.
[62] J. Polli,et al. Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer , 2012, Pharmaceutical Research.
[63] Chris Twelves,et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study , 2011, The Lancet.
[64] Mafalda Oliveira,et al. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab , 2011, Breast Cancer Research and Treatment.
[65] L. Collette,et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] M. Mehta,et al. Why avoid the hippocampus? A comprehensive review. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[67] Karen Gelmon,et al. Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] A. Baschnagel,et al. Surgical Resection of Brain Metastases and the Risk of Leptomeningeal Recurrence in Patients Treated With Stereotactic Radiosurgery. , 2009, International journal of radiation oncology, biology, physics.
[69] K. Hess,et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. , 2009, The Lancet. Oncology.
[70] R. Greil,et al. Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer , 2009, Clinical Cancer Research.
[71] R. Béliveau,et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2 , 2008, British journal of pharmacology.
[72] Hans-Jakob Steiger,et al. Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial , 2008, Journal of Neuro-Oncology.
[73] Kelly A. Harmon,et al. The Role of Efflux and Uptake Transporters in N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions , 2008, Drug Metabolism and Disposition.
[74] D. Kondziolka,et al. TUMOR BED RADIOSURGERY AFTER RESECTION OF CEREBRAL METASTASES , 2008, Neurosurgery.
[75] Akash J. Patel,et al. Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. , 2008, Journal of neurosurgery.
[76] M. Casey,et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses , 2008, Breast Cancer Research and Treatment.
[77] H. Shirato,et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. , 2007, International journal of radiation oncology, biology, physics.
[78] M. Vogelbaum,et al. Resectable brain metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] Maria Werner-Wasik,et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.
[80] B. Pestalozzi,et al. Trastuzumab in CSF. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] G. Duncan,et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis , 1996, Cancer.
[82] Ronald Brand,et al. Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery , 1993, Annals of neurology.
[83] Y Maruyama,et al. A randomized trial of surgery in the treatment of single metastases to the brain. , 1990, The New England journal of medicine.
[84] L. Deangelis,et al. Radiation‐induced dementia in patients cured of brain metastases , 1989, Neurology.
[85] Eudocia Q Lee,et al. Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. , 2018, The Lancet. Oncology.
[86] W. Gradishar,et al. Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[87] L. Collette,et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] M. Campone,et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. , 2013, The Lancet. Oncology.
[89] Kelly A. Harmon,et al. The Role of Efflux and Uptake Transporters in N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions , 2008, Drug Metabolism and Disposition.
[90] P. Brown,et al. Properly Selected Patients with Multiple Brain Metastases May Benefit from Aggressive Treatment of their Intracranial Disease , 2004, Journal of Neuro-Oncology.
[91] M. Mehta,et al. A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. , 1996, International journal of radiation oncology, biology, physics.